Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

In the European Union, it is indicated in combination with trastuzumab and capecitabine for the treatment of adults with HER2‑positive locally advanced or metastatic breast cancer who have received at least two prior anti‑HER2 treatment regimens.

In January 2023, the US Food and Drug Administration (FDA) granted accelerated approval to tucatinib in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

tucatinib is available in India on request-

Lucknow Speciality Pharma is the leading Pharma brand and one of the most leading Pharma Wholesalers in Lucknow. We are expanding our reach across India. To get “TUKYSA (tucatinib) tablet“, patients can simply fill the order form or can send mail at info@lucknowpharma.com. Patients can also send WhatsApp messages to +91-9555306364, The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.